BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) CMO Todd Berard sold 424 shares of the business's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $25.46, for a total transaction of $10,795.04. Following the completion of the transaction, the chief marketing officer now owns 106,538 shares of the company's stock, valued at approximately $2,712,457.48. This trade represents a 0.40 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Todd Berard also recently made the following trade(s):
- On Wednesday, February 12th, Todd Berard sold 102 shares of BioLife Solutions stock. The stock was sold at an average price of $26.54, for a total transaction of $2,707.08.
- On Monday, January 6th, Todd Berard sold 343 shares of BioLife Solutions stock. The stock was sold at an average price of $27.02, for a total transaction of $9,267.86.
BioLife Solutions Stock Performance
NASDAQ BLFS traded down $0.97 during trading on Friday, reaching $25.83. The company's stock had a trading volume of 608,317 shares, compared to its average volume of 283,669. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78. The firm has a market cap of $1.21 billion, a price-to-earnings ratio of -24.37 and a beta of 2.04. BioLife Solutions, Inc. has a twelve month low of $14.84 and a twelve month high of $29.55. The business's fifty day moving average price is $26.65 and its 200-day moving average price is $25.49.
BioLife Solutions (NASDAQ:BLFS - Get Free Report) last issued its quarterly earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.06) by $0.32. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. The business had revenue of $22.71 million for the quarter, compared to analyst estimates of $21.73 million. During the same period in the previous year, the business posted ($0.21) earnings per share. As a group, analysts anticipate that BioLife Solutions, Inc. will post -0.3 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently made changes to their positions in BLFS. Steward Partners Investment Advisory LLC acquired a new position in BioLife Solutions during the fourth quarter worth about $26,000. Mark Sheptoff Financial Planning LLC acquired a new position in BioLife Solutions during the third quarter worth about $28,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in BioLife Solutions during the fourth quarter worth about $31,000. Quest Partners LLC acquired a new position in BioLife Solutions during the third quarter worth about $57,000. Finally, 1620 Investment Advisors Inc. grew its position in BioLife Solutions by 41.7% during the fourth quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider's stock worth $60,000 after buying an additional 675 shares during the period. 93.24% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Several research firms have recently issued reports on BLFS. Benchmark reaffirmed a "buy" rating and set a $30.00 price objective on shares of BioLife Solutions in a research report on Thursday, December 19th. TD Cowen lifted their price objective on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock a "buy" rating in a research report on Wednesday, November 13th. Northland Securities lifted their price objective on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock an "outperform" rating in a research report on Wednesday, January 8th. Craig Hallum lifted their price objective on shares of BioLife Solutions from $30.00 to $32.00 and gave the stock a "buy" rating in a research report on Wednesday, November 13th. Finally, KeyCorp boosted their price target on shares of BioLife Solutions from $30.00 to $33.00 and gave the company an "overweight" rating in a research report on Friday, December 13th. One analyst has rated the stock with a sell rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $29.86.
Get Our Latest Stock Report on BioLife Solutions
About BioLife Solutions
(
Get Free Report)
BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.
Read More
Before you consider BioLife Solutions, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioLife Solutions wasn't on the list.
While BioLife Solutions currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
